Allergic Rhinitis, Seasonal Allergic Rhinitis
Conditions
Brief summary
This is a post-marketing surveillance study on a marketed cetrizine hydrochloride formulation.
Interventions
OTHERCetrizine hydrochloride
As provided on the patient information leaflet
Sponsors
GlaxoSmithKline
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male and female participants, between 15-65 years of age, who purchase the marketed cetrizine hydrochloride formulation
Exclusion criteria
* Who have ever experienced allergic symptoms by taking this medication or any component of this medication, piperazine derivative (including levocetirizine, hydroxizine) * Those who have been under 15en diagnosed with kidney disease * Children under 15 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events after having cetrizine hydrochloride | At baseline | Participants will answer a questionnaire which consists of questions on safety of the marketed cetrizine hydrochloride formulation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of the marketed cetrizine hydrochloride formulation | At baseline | Participants will answer a questionnaire which consists of questions on their satisfaction after taking the marketed cetrizine hydrochloride formulation. The efficacy will be measured on a 4 point scale (1 Efficacious; 2 Somewhat efficacious; 3 Not efficacious; 4 Not known) |
Countries
Japan
Outcome results
None listed